This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress taking place in
San FranciscoApril 19-23. The podium presentation, "Effect of an Anti-inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis During IOL Replacement Surgery," summarizes key analyses of Phase 2 and Phase 3 clinical data assessing the ability of OMS302 to reduce the incidence of miosis (pupil constriction) during intraoperative lens replacement surgery. These analyses will be included in both the US and European marketing applications for OMS302.
Steve Whitaker, M.D., Omeros' vice president of clinical development and chief medical officer, will present the data at
3:27 p.m. PDT on
April 21 in the Intraocular Surgery/Medications Session.
About Omeros' OMS302 ProgramOMS302 is Omeros' product being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently completed its successful OMS302 Phase 3 clinical program and expects to submit a New Drug Application to the U.S. Food and Drug Administration this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.
ILR involves replacement of the original lens of the eye with an artificial intraocular lens. These procedures are typically performed to replace a lens opacified by a cataract or to correct a refractive error of the lens (i.e., refractive lens exchange). OMS302 is added to standard irrigation solution used in ILR and delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.